| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633272 | GD SEARLE | Substituted isoxazoles for the treatment of inflammation |
Feb, 2015
(9 years ago) | |
Bextra is owned by Gd Searle.
Bextra contains Valdecoxib.
Bextra has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Bextra are:
- US5633272
Bextra was authorised for market use on 16 November, 2001.
Bextra is available in tablet;oral dosage forms.
Bextra can be used as signs and symptoms of osteoarthritis and adult rheumatoid arthritis and treatment of primary dysmenorrhea.
The generics of Bextra are possible to be released after 13 February, 2015.
Drugs and Companies using VALDECOXIB ingredient
Market Authorisation Date: 16 November, 2001
Treatment: Signs and symptoms of osteoarthritis and adult rheumatoid arthritis and treatment of primary dysmenorrhea
Dosage: TABLET;ORAL
More Information on Dosage
BEXTRA family patents
